Iovance Biotherapeutics, Inc. IOVA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s accrued expenses?
- Iovance Biotherapeutics, Inc. (IOVA) reported accrued expenses of $88.07M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s accrued expenses changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accrued expenses increased by 4.0% year-over-year, from $84.71M to $88.07M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s accrued expenses has grown at a 25.9% compound annual growth rate (CAGR), from $35.07M to $111.16M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.